CFTR and cystic fibrosis: Despite the current ivacaftor/lumacaftor combination therapy (Orkambi and more recently Trikafta from Vertex Pharmaceuticals) designed for CF patients with the genetic F508del mutation in homozygosity have a good efficacy [20], treatment of lung pathology in CF would take advantage from antimicrobial compounds with a repairing action of the lung epithelium in addition to a potentiation of CFTR activity.